TNFRSF17 and Miyoshi myopathy: This study demonstrated a highly remarkable ORR of 100% (89% ≥VGPR) at the recommended phase II dose in anti-BCMA/-GPRC5D naïve patients [14], and this concept is now being taken forward by innovative phase-2 trial concepts, including the MajesTEC-5/GMMG-10/DSMM-20 study (NCT05695508), which combines sequential targeting of BCMA and GPRC5D for unprecedented depth of response in patients with newly diagnosed MM [15].